Search Results
Life Is What You Make It
I am Len Strickland and I was diagnosed with Hereditary Amyloidosis (ATTR) with a variant of Val122ile. There are over 100 different variants of ATTR based on culture and ethnicity. I learned of my affliction at the Mayo Clinic in Rochester, Minnesota on March 29 of 2007. Hereditary Amyloidosis (ATT…
moreMan Survives Cardiac Arrest, Benefits from First-Ever Drug for Rare Form of Heart Failure
Shared by Stephen Sroka, PhD, from the Cleveland Clinic website On the short helicopter ride to Cleveland Clinic from the Medina, Ohio, school where 800 people witnessed his sudden cardiac arrest, Dr. Stephen Sroka – on the brink of death — had an epiphany. “I was barely conscious, but kept thinkin…
moreU.S. FDA APPROVES VYNDAQEL® AND VYNDAMAX™ FOR USE IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, A RARE AND FATAL DISEASE
— FIRST AND ONLY MEDICINES APPROVED FOR PATIENTS WITH EITHER WILD-TYPE OR HEREDITARY TRANSTHYRETIN AMYLOID CARDIOMYOPATHY — Monday, May 6, 2019 – 6:45am EDT Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and V…
moreUS FDA ACCEPTS REGULATORY SUBMISSIONS FOR REVIEW OF TAFAMIDIS TO TREAT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Monday, January 14, 2019 – 8:00am EST Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs…
morePfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy
Pfizer Inc. announced today that the FDA granted Fast Track designation to tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure. Currently in Phase 3 clinical development for TTR-CM, tafamidis is…
moreFacts
Clear information on the main amyloidosis diseases, including symptoms, diagnosis, treatments and FAQs.
moreThe Amyloidosis Foundation Spreads Awareness Through ‘Amyloidosis Awareness Month’ in March 2020
Most people are unfamiliar with amyloidosis, often diagnosed late since they are unaware of what this rare disease is or what symptoms to look for. The Amyloidosis Foundation is working to change that, declaring March as Amyloidosis Awareness Month. We began in 2018, by passing state resolutions to…
moreGenetic Disease More Common Among African Americans Can Now Be Treated
Brandpoint (BPT) – Posted: Wednesday, December 11, 2019 4:31 am (BPT) – A disease called hereditary ATTR amyloidosis (hATTR) is linked to a genetic mutation that has been passed through generations of Americans with ancestors from West African countries such as Ghana, Sierra Leone, Co…
moreAmyloidosis Foundation Announces 2020 Research Grant Recipients
We are pleased to announce the funding of three new research projects. The Donald C. Brockman Memorial Research Grant has been awarded to Mark Rank, PhD of Johns Hopkins University. His study revolves around cardiac amyloidosis. The David Seldin, MD, PhD Memorial Research Grant recipient is Susan Ba…
more